Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.

Inclusion Criteria: * Participant must be 45 years of age and older at the time of signing the informed consent * Non-cardioembolic ischemic stroke with * persistent signs and symptoms of stroke lasting for ≥ 24 hours OR * acute brain infarction documented by computed tomography (CT) or MRI AND * with the intention to be treated with antiplatelet therapy during the study conduct * Imaging of brain (CT or MRI) ruling out hemorrhagic stroke or another pathology that could explain symptoms (e.g. brain tumor, abscess, vascular malformation) * Severity of index event nearest the time of randomization: * Part A: minor stroke (defined as National Institutes of Health Stroke Scale (NIHSS) ≤ 7) can be enrolled * Part B: participants with minor or moderate stroke and NIHSS ≤ 15 can be enrolled. Participants undergoing thrombolysis or endovascular therapy (mechanical thrombectomy) can be enrolled but at the earliest 24 hours after the intervention * Randomization within 48 hours after the onset of symptoms of the index event (or after patients were last known to be without symptoms in case of wake-up stroke) * Ability to conduct an MRI either before randomization or within 72 hours after randomization Exclusion Criteria: * Prior ischemic stroke within last 30 days of index event * History of atrial fibrillation or suspicion of cardioembolic source of stroke * Dysphagia with inability to safely swallow study medication * Contraindication to perform brain MRI * Part A only:…